CD274 and non-small cell lung carcinoma: One of these studies is KEYNOTE-024 (KN024), which established single-agent pembrolizumab for the treatment of advanced NSCLC with PD-L1 expression ≥ 50%, demonstrating significantly longer progression-free (PFS) and overall survival (OS) compared with the investigator’s choice of platinum-based chemotherapy [4,5,6].